ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors

Hong, Chang; Dong, Han-Zhi; Li, Rui-Ning; Zhu, Hong-Bo; Li, Qi-Mei; Cui, Hao; Hu, Cheng-Yi; Huang, Chao-Yi; Peng, Jie; Liu, Li*; Zou, Xue-Jing*; Xiao, Lu-Shan*南方医科大学; 1
DIGESTIVE DISEASES2023-5DOI: 10.1159/000527574
3被引11阅读
引用收藏
分享

摘要

Background: Immune checkpoint inhibitors (ICIs) have improved survival outcomes and resulted in long-term responses in primary liver cancer in some patients. Nevertheless, not all patients with PLC could benefit from immunotherapy. Therefore, it is necessary to identify patients suitable for such therapy. Methods: 215 patients with primary liver cancer with immunotherapy from Nanfang Hospital were screened between August 2018 and October 2020 as a training set and our validation set included 71 patients of hepatocellular carcinoma from Jiangxi Cancer Hospital from May 2019 to July 2021. The primary endpoint was the disease control rate ( DCR), and the secondary endpoints were overall survival (OS) and progression-free survival. Results: In the training set, neutrophil-lymphocyte ratio (NLR) >= 3 and alpha-fetoprotein (AFP) level >= 20 ng/mL were independently associated with non-DCR in the training set after adjusting for distant metastasis at baseline and targeted therapy combination. Furthermore, a hepatic immune predictive index (HIPI) based on NLR and AFP level was developed and patients with poor HIPI associated with worse clinical outcomes. In validation set, high HIPI was associated with poor OS. Conclusion: HIPI, based on NLR and AFP level, is an effective indicator in ICI-treated patients with primary liver cancer. Our findings may help guide the selection and on-treatment strategies for immunotherapies for primary liver cancer patients.

学科与关键词

关键词
Alpha-fetoproteinHepatic immune predictive indexImmune checkpoint inhibitorsNeutrophil-lymphocyte ratioPrimary liver cancer
相关
加载中…
  • Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors
    Xiao, Lu-Shan; Li, Qi-Mei; Hu, Cheng-Yi; Cui, Hao; Hong, Chang; Huang, Chao-Yi; Li, Rui-Ning; Dong, Zhong-Yi; Zhu, Hong-Bo; Liu, Li*Annals of Palliative Medicine, 2021, 10(11): 11244-+.被引 7
  • Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors
    Xiao, Lu-Shan; Hu, Cheng-Yi; Cui, Hao; Li, Rui-Ning; Hong, Chang; Li, Qi-Mei; Huang, Chao-Yi; Dong, Zhong-Yi; Zhu, Hong-Bo; Liu, Li*Cancer Medicine, 2022, 11(24): 4880-4888.被引 7
  • Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
    Zhang, Rujia; Zhao, Haoran; Wang, Peng; Guo, Zuoming; Liu, Chunxun; Qu, Zhaowei*BMC CANCER, 2023, 23(1): 1181.
查看全部 →

发表信息

论文状态
公开发表
期刊
DIGESTIVE DISEASES
发表日期
2023-05
卷期
第 41 卷, 第 3 期
页码
422-430
DOI
10.1159/000527574
语言
ENGLISH
成果收录
SCIE
资助标注
National Nature Science Foundation of China [81972897, 82172751, 82002549]; China Postdoctoral Science Foundation [2021M701629]; Guangzhou Science and Technology Project [202201011183]; Guangdong Natural Science Foundation [2019A1515110629]

作者

  • H

    Hong, Chang (第一作者)

    southern med univ

  • D

    Dong, Han-Zhi

    2 · jiangxi canc hosp

查看全部 12 位作者收起作者
  • L

    Li, Rui-Ning

    southern med univ

  • Z

    Zhu, Hong-Bo

    1 · univ south china

  • L

    Li, Qi-Mei

    southern med univ

  • C

    Cui, Hao

    southern med univ

  • H

    Hu, Cheng-Yi

    southern med univ

  • H

    Huang, Chao-Yi

    southern med univ

  • P

    Peng, Jie

    2

  • L

    Liu, Li (通讯)

    southern med univ

  • Z

    Zou, Xue-Jing (通讯)

    southern med univ

  • X

    Xiao, Lu-Shan (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417